SANTA CLARA, Calif. / Sep 03, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced its participation as a premium sponsor at the upcoming European Congress of Pathology (ECP) 2025, taking place in Vienna, Austria, from September 6–10, 2025. Agilent will spotlight the European launch of its newly expanded Dako Omnis Family of instruments.
The Dako Omnis family, including the Dako Omnis 110, 165, and 165 Duo models, is built to provide flexibility, consistency, and efficiency across labs of all sizes. Designed to meet the evolving needs of modern pathology labs, these instruments, are backed up by Agilent’s dedicated service and support teams to help ensure reliable operations and confident diagnoses.
“Our presence at ECP 2025 underscores Agilent’s dedication to supporting diagnostic excellence,” said Majken Nielsen, associate vice president of Marketing and Product Management, Clinical Diagnostics Division at Agilent. “The launch of the Dako Omnis family is a direct response to the challenges that labs face today. It marks a significant milestone in Agilent’s commitment to delivering scalable, high-performance diagnostic solutions that empower labs to meet increasing demands with confidence.”
As a premium sponsor, visitors to the Agilent booth will have the opportunity to:
To see these innovations and more, visit Agilent at ECP 2025 in Vienna, at booth #18.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
Last Trade: | US$126.72 |
Daily Change: | -0.47 -0.37 |
Daily Volume: | 1,773,702 |
Market Cap: | US$35.930B |
September 02, 2025 August 20, 2025 August 04, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load